Ads from a group dubbed “Defend Our DNA” have emerged as lawmakers in debate legislation that would restrict federal business with certain Chinese biotechs.
BIO undergoes significant restructuring, lays off execs amid industry woes
The internal restructuring comes months after John Crowley, an alum of Bristol Myers Squibb, Novazyme and Amicus Therapeutics, took over as CEO of BIO.
Boehringer Ingelheim teams with Ochre Bio on $1.3B deal to combat MASH
The deal represents an expansion of Boehringer Ingelheim’s investments in the CLD treatment space and scales Ochre Bio’s ambitions, specifically around MASH cirrhosis.
AI Deciphered: Discovering the Potential for Marketers and Communicators